Blood–Brain Barrier Disruption in Neuroimmunological Disease
International Journal of Molecular Sciences · 02.10.2024 · 25 (19) · 10625
DOI: 10.3390/ijms251910625 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.10.2024. Verfasst von Fumitaka Shimizu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Endoplasmic Reticulum Chaperone BiP, Autoantibodies, Multiple Sclerosis. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kakenhi from the Japan Society for the Promotion of Science, Tokyo, Japan, Grants-in-Aid for Scientific Research, Chugai Foundation for Innovative Drug Discovery Science and BRAIN SCIENCE FOUNDATION.
Abstract (Originalsprache)
The blood–brain barrier (BBB) acts as a structural and functional barrier for brain homeostasis. This review highlights the pathological contribution of BBB dysfunction to neuroimmunological diseases, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), autoimmune encephalitis (AE), and paraneoplastic neurological syndrome (PNS). The transmigration of massive lymphocytes across the BBB caused by the activation of cell adhesion molecules is involved in the early phase of MS, and dysfunction of the cortical BBB is associated with the atrophy of gray matter in the late phase of MS. At the onset of NMOSD, increased permeability of the BBB causes the entry of circulating AQP4 autoantibodies into the central nervous system (CNS). Recent reports have shown the importance of glucose-regulated protein (GRP) autoantibodies as BBB-reactive autoantibodies in NMOSD, which induce antibody-mediated BBB dysfunction. BBB breakdown has also been observed in MOGAD, NPSLE, and AE with anti-NMDAR antibodies. Our recent report demonstrated the presence of GRP78 autoantibodies in patients with MOGAD and the molecular mechanism responsible for GRP78 autoantibody-mediated BBB impairment. Disruption of the BBB may explain the symptoms in the brain and cerebellum in the development of PNS, as it induces the entry of pathogenic autoantibodies or lymphocytes into the CNS through autoimmunity against tumors in the periphery. GRP78 autoantibodies were detected in paraneoplastic cerebellar degeneration and Lambert–Eaton myasthenic syndrome, and they were associated with cerebellar ataxia with anti-P/Q type voltage-gated calcium channel antibodies. This review reports that therapies affecting the BBB that are currently available for disease-modifying therapies for neuroimmunological diseases have the potential to prevent BBB damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan.
ORCID-Profile: Fumitaka Shimizu
Förderung
- Kakenhi from the Japan Society for the Promotion of Science, Tokyo, Japan
- Grants-in-Aid for Scientific Research
- Chugai Foundation for Innovative Drug Discovery Science and BRAIN SCIENCE FOUNDATION
Zitieren
APA
Shimizu, F., & Nakamori, M. (2024). Blood–Brain Barrier Disruption in Neuroimmunological Disease. International Journal of Molecular Sciences, 25(19), 10625. https://doi.org/10.3390/ijms251910625
Vancouver
Shimizu F, Nakamori M. Blood–Brain Barrier Disruption in Neuroimmunological Disease. International Journal of Molecular Sciences. 2024;25(19):10625. doi:10.3390/ijms251910625
BibTeX
@article{Shimizu2024,
author = {Shimizu, Fumitaka and Nakamori, Masayuki},
title = {Blood–Brain Barrier Disruption in Neuroimmunological Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {19},
pages = {10625},
doi = {10.3390/ijms251910625}
}
EUVIMED